JY
ATYR

Jeff Yass’s aTyr Pharma ATYR Stock Holding History

Jeff Yass’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
747,039
-119,705
-14% -$78.2K ﹤0.01% 10172
2026
Q1 		$676K Buy
866,744
+102,001
+13% +$86.1K ﹤0.01% 8884
2025
Q4 		$599K Buy
764,743
+638,071
+504% +$524K ﹤0.01% 8376
2025
Q3 		$91.4K Sell
126,672
-127,346
-50% -$577K ﹤0.01% 11619
2025
Q2 		$1.29M Sell
254,018
-1,479,063
-85% -$5.82M ﹤0.01% 6798
2025
Q1 		$5.23M Buy
1,733,081
+945,239
+120% +$3.45M ﹤0.01% 3566
2024
Q4 		$2.85M Buy
787,842
+654,613
+491% +$1.98M ﹤0.01% 4571
2024
Q3 		$234K Buy
+133,229
New +$242K ﹤0.01% 10140
2023
Q3 		– Sell
-46,634
Closed -$101K – 13169
2023
Q2 		$101K Buy
+46,634
New +$102K ﹤0.01% 10943
2022
Q4 		– Sell
-45,542
Closed -$137K – 13886
2022
Q3 		$137K Sell
45,542
-997
-2% -$3.34K ﹤0.01% 11371
2022
Q2 		$132K Buy
+46,539
New +$168K ﹤0.01% 11192
2021
Q4 		– Sell
-81,781
Closed -$682K – 14051
2021
Q3 		$743K Buy
81,781
+70,942
+655% +$424K ﹤0.01% 8344
2021
Q2 		$53K Buy
+10,839
New +$46.2K ﹤0.01% 12285
2020
Q2 		– Sell
-10,268
Closed -$29K – 11078
2020
Q1 		$29K Buy
+10,268
New +$44.3K ﹤0.01% 9839
2019
Q1 		– Sell
-7,083
Closed -$49K – 9997
2018
Q4 		$49K Buy
7,083
+1,878
+36% +$15.7K ﹤0.01% 8490
2018
Q3 		$59K Buy
+5,205
New +$57K ﹤0.01% 8797
2017
Q2 		– Sell
-1,381
Closed -$68K – 9942
2017
Q1 		$68K Buy
+1,381
New +$63.1K ﹤0.01% 8519

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's ATYR Position: Q2 2026 in Review

Jeff Yass reduced its aTyr Pharma (ATYR) stake by 14% in Q2 2026, selling an estimated $78.2K and leaving 747,039 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #10172.

Jeff Yass first reported a position in ATYR in Q1 2017 and has held it in 17 quarters since. The position peaked at $5.23M in Q1 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Jeff Yass held 747,039 shares of aTyr Pharma worth $446K as of Q2 2026.
  • Jeff Yass sold 119,705 aTyr Pharma shares in Q2 2026, an estimated $78.2K.
  • aTyr Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10172 holding.
  • Jeff Yass first reported a position in aTyr Pharma in Q1 2017 and has held it in 17 quarters since.
  • Jeff Yass's aTyr Pharma position peaked at $5.23M in Q1 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.